CompletedNot Applicable

An Examination of Visual Perceptual Training

Canada73 participantsStarted 2017-06-28

Plain-language summary

Perceptual-cognitive training (PCT) is a computerized software game has been shown to improve sport performance in young elite athletes and even to aid in recovery speeds post-concussion. PCT may represent a unique type of training that could ultimately enhance cognitive performance or quality of life in all populations. What is not clear is whether PCT is beneficial to older adults with subjective memory complaints (SMCs). SMCs in older adults are an early risk indicator for Alzheimer's disease, making older adults with SMCs a target population for proactive interventions. The aim of this study was to determine if PCT can serve as a proactive intervention and enhance cognitive abilities in older adults with SMCs. The results of this research protocol introduce a new way of prevention from cognitive decline in healthy older adults and may introduce a new training programs for age-related memory disorder.

Who can participate

Age range

60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 60 and over; * Have subjective cognitive complaints; * The results of the screening test Mini Mental State Examination (MMSE) should be ≥ 24 (this test is used only at baseline visit to verify if the participant might be included in the sample or not). Exclusion Criteria: * Presence of medical diagnosis of a Major Neurocognitive Disorder (e.g. Alzheimer's disease, front temporal lobe dementia, Lewy Body dementia, vascular dementia), * Presence of sensory deficits (e.g. colour blindness, monocular/binocular blindness, macular degeneration), * Presence of psychiatric disorders (i.e. depression, anxiety), * The participants with scores under 24 at MMSE screening test will be excluded and sent to the family doctor (i.e. to minimize the risk of including people with pre-clinical dementia).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in memory performance in older adults with SMCs

Timeframe: First neuropsychological assessment (Baseline). After seven week period both groups underwent the second neuropsychological assessment (Week 7). After eleven weeks a follow-up assessment was conducted (Week 11).

Trial details

NCT IDNCT03763344

SponsorUniversity of Victoria

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06-30

View on ClinicalTrials.gov More Age-Related Memory Disorders trials